A Phase 3 interventional study of Upadacitinib and Corticosteroid (CS) in Giant Cell Arteritis (GCA), sponsored by AbbVie. Completed at 172 sites in 24 countries. Open to participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2026-02-24.
Sponsored by AbbVie · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 35 studies in Giant Cell Arteritis with a site in United States — 8 open to participants now, 8 under way, 1 of them phase 3. Giant Cell Arteritis · United States.
Among the 35 studies in Giant Cell Arteritis with a site in United States, this one has the largest enrollment of the 20 interventional ones that give a count, is one of 3 that started in 2019, is one of 7 in phase 3, and was the 24th registered.
149 studies on the registry are indexed under Giant Cell Arteritis; 50 are open to participants now.
Browse Giant Cell Arteritis studies →8 of the 35 studies in Giant Cell Arteritis with a site in United States are open now. Recruiting first, the newest first:
National Institute of Allergy and Infectious Diseases (NIAID) · Sites in United States
Ages 50+
NYU Langone Health · Sites in United States
Ages 18+
University of Pennsylvania · Sites in United States, Canada, Germany
Ages 50+
Yale University · Sites in United States
Ages 18–99 · Healthy volunteers
University of Pennsylvania · Sites in United States, Canada, Germany
Ages 50+ · Healthy volunteers
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 36 Giant Cell Arteritis studies recruiting now, 34 (94%) set no upper age limit and none (0%) stop at 75 or younger; 4 take children under 18; 9 take healthy volunteers.
This study: 50 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
35 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 9 · Phase 3 7 · Phase 4 1
First in 2000; this study’s year is marked. 3 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 429 is above the median of 64 across 65 interventional studies indexed under Giant Cell Arteritis.
Median enrollment 68 across the 20 interventional studies, 467 across the 15 observational. Of the 23 that completed or were terminated, 11 (48%) have results posted.
This tab as a report to print or save as PDF → With an account.
10 of 35 have an industry lead sponsor. The 10 most frequent:
AbbVie is the lead sponsor of 977 studies on the registry; 136 are open to participants now.
Of its 359 completed or terminated interventional studies of FDA-regulated products, 215 (60%) have results posted.
AbbVie has 2 studies filed under Giant Cell Arteritis — fewer than ten, so there is no comparison to draw.
1 of the studies in Giant Cell Arteritis with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07108387National Institute of Allergy and Infectious Diseases (NIAID)Tocilizumab Discontinuation Versus Dose Reduction for Patients With Well-Controlled Giant Cell Arteritis | 2027-06-11 |
Add it to your calendar (.ics) → With an account.
Among the 35 studies in Giant Cell Arteritis with a site in United States, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study consists of two periods. The objective of Period 1 is to evaluate the efficacy of upadacitinib in combination with a 26-week corticosteroid (CS) taper regimen compared to placebo in combination with a 52-week CS taper regimen, as measured by the proportion of participants in sustained remission at Week 52, and to assess the safety and tolerability of upadacitinib in participants with giant cell arteritis (GCA). The objective of Period 2 is to evaluate the safety and efficacy of continuing versus withdrawing upadacitinib in maintaining remission in participants who achieved sustained remission in Period 1.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Diagnosis of giant cell arteritis (GCA) according to the following criteria:
Exclusion Criteria:
Use of any of the following systemic treatments within the specified timeframe prior to study start:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received placebo tablets for upadacitinib administered orally once daily (QD) for 52 weeks and a 52-week corticosteroid (CS) taper regimen during Period 1.
Drug: Corticosteroid (CS) · Other: Placebo
Participants received 7.5 mg upadacitinib tablets administered orally once daily (QD) for 52 weeks and a 26-week corticosteroid (CS) taper regimen during Period 1.
Drug: Upadacitinib · Drug: Corticosteroid (CS)
Participants received 15 mg upadacitinib tablets administered orally once daily (QD) for 52 weeks and a 26-week corticosteroid (CS) taper regimen during Period 1.
Drug: Upadacitinib · Drug: Corticosteroid (CS)
Participants who achieved sustained remission for at least 24 weeks prior to the Week 52 visit (at the end of Period 1) OR at remission at the Week 52 visit only who were assigned to placebo tablets for upadacitinib administered orally once daily (QD) in Period 1 continued to receive placebo tablets for upadacitinib administered orally once daily (QD) in Period 2.
Other: Placebo
Participants received 7.5 mg upadacitinib tablets administered orally once daily (QD) in Period 2.
Drug: Upadacitinib
Participants received placebo tablets for upadacitinib administered orally once daily (QD) in Period 2.
Other: Placebo
Participants received 15 mg upadacitinib tablets administered orally once daily (QD) in Period 2.
Drug: Upadacitinib
Participants received placebo tablets for upadacitinib administered orally once daily (QD) in Period 2.
Other: Placebo
Administered orally once a day
Also known as: ABT-494, RINVOQ
At Baseline, all participants switched to corticosteroids (CS) provided by the sponsor with the oral prednisone or prednisolone dose at 20, 30, 40, 50, or 60 mg QD. The initial dose of prednisone or prednisolone was at the discretion of the investigator, based on disease severity and comorbid medical conditions, at a minimum of 20 mg QD at Baseline. At Baseline, if a participant was on a dose other than 20, 30, 40, 50, or 60 mg QD, the dose was rounded up or down, as clinically indicated per investigator discretion, to the nearest of these doses. Prednisone or prednisolone was tapered according to a predefined schedule over a 26- or 52-week period. Open-label prednisone or prednisolone was provided until the dose was tapered to 20 mg/day. Subsequently, blinded prednisone or prednisolone was provided for the remaining blinded taper regimen through Week 52.
Administered orally once a day
Percentage of Participants Achieving Sustained Remission at Week 52
Sustained remission is defined as having achieved absence of giant cell arteritis (GCA) signs and symptoms from Week 12 through Week 52, and adherence to the protocol-defined corticosteroid (CS) taper regimen.
Time frame: From Week 12 to Week 52
Percentage of Participants Achieving Sustained Complete Remission From Week 12 Through Week 52
Sustained complete remission is defined as having absence of giant cell arteritis (GCA) signs and symptoms from Week 12 through Week 52; normalization of erythrocyte sedimentation rate (ESR); normalization of high sensitivity C-reactive protein (hs-CRP) and adherence to the protocol-defined CS taper regimen.
Time frame: Week 12 through Week 52
Cumulative Corticosteroid (CS) Exposure Through Week 52
The cumulative exposure to corticosteroid(s) through Week 52 of the study was documented.
Time frame: Baseline up to Week 52
Time to First Disease Flare Through Week 52
Disease flare is defined as an event determined by the investigator to represent recurrence of Giant Cell Arteritis (GCA) signs or symptoms or an erythrocyte sedimentation rate (ESR) measurement \> 30 mm/hr (attributable to GCA) AND requiring an increase in corticosteroid (CS) dose.
Time frame: Baseline up to Week 52
Percentage of Participants Who Experience at Least 1 Disease Flare Through Week 52
The percentage of participants who experience at least 1 disease flare was calculated. Disease flare is defined as an event determined by the investigator to represent recurrence of Giant Cell Arteritis (GCA) signs or symptoms or an erythrocyte sedimentation rate (ESR) measurement \> 30 mm/hr (attributable to GCA) AND requiring an increase in corticosteroid (CS) dose.
Time frame: Baseline up to Week 52
Percentage of Participants in Complete Remission at Week 52
Complete remission is defined as having achieved absence of Giant Cell Arteritis (GCA) signs and symptoms; normalization of erythrocyte sedimentation rate (ESR) to \< 30 mm/hr-- if ESR ≥30 mm/hr and elevation is not attributable to GCA, this criterion can still be met); normalization of high sensitivity C-reactive protein (hs-CRP) to \< 1 mg/dL; and adherence to the protocol-defined corticosteroid (CS) taper regimen.
Time frame: At Week 52
Percentage of Participants in Complete Remission at Week 24
Complete remission is defined as having achieved absence of Giant Cell Arteritis (GCA) signs and symptoms; normalization of erythrocyte sedimentation rate (ESR) to \< 30 mm/hr-- if ESR ≥30 mm/hr and elevation is not attributable to GCA, this criterion can still be met); normalization of high sensitivity C-reactive protein (hs-CRP) to \< 1 mg/dL; and adherence to the protocol-defined corticosteroid (CS) taper regimen.
Time frame: At Week 24
Change From Baseline in the 36-item Short Form Quality of Life Questionnaire (SF-36) Physical Component Summary (PCS) Score at Week 52
The Short Form 36-Item Health Survey (SF-36) Version 2 is a self-administered questionnaire that measures the impact of disease on overall quality of life during the past 4 weeks. The SF-36 consists of 36 questions in eight domains (physical function, pain, general and mental health, vitality, social function, physical and emotional health). The physical component summary (PCS) is a weighted combination of the 8 subscales with positive weighting for physical functioning, role-physical, bodily pain, and general health. The SF-36 PCS ranges from 0 to 100. A linear algorithm was applied to the calculation of the PCS which has a normative mean value of 50. Higher scores are associated with less disability; a score of 100 is equivalent to no disability and a score of 0 is equivalent to maximum disability. A positive change from the Baseline score indicates improvement.
Time frame: Baseline, Week 52
Number of Disease Flares Per Participant Through Week 52
The number of disease flares per participant during Period 1 was documented, and was adjusted by the duration of study participation.
Time frame: Baseline up to Week 52
Change From Baseline in Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-Fatigue) at Week 52
The FACIT-Fatigue questionnaire is a self-administered patient questionnaire that consists of 13 questions designed to measure the degree of fatigue experienced by participants in the previous 7 days, including physical fatigue, functional fatigue, emotional fatigue, and social consequences of fatigue. Participants respond to the questions on a scale from 0 (not at all) to 4 (very much). The FACIT-Fatigue score is computed by summing the item scores, after reversing items worded in the negative direction. The FACIT-Fatigue score ranges from 0 to 52, where higher scores represent less fatigue. A positive change from Baseline indicates improvement.
Time frame: Baseline, Week 52
Assessment of Treatment Satisfaction Questionnaire for Medication (TSQM) Patient Global Satisfaction Subscale at Week 52
The Treatment Satisfaction Questionnaire for Medications (TSQM) is a generic ePRO measure of treatment satisfaction, developed to compare treatment satisfaction between medication types and conditions. TSQM comprises of 14 items to assess 4 domains (effectiveness, side effects, convenience, and global satisfaction). The TSQM items are rated on a Likert scale (1 = extremely dissatisfied to 7 = extremely satisfied). Scores for each of the 4 domains range from 0 to 100, with higher scores corresponding to higher satisfaction. A positive change from Baseline indicates improvement.
Time frame: At Week 52
Rate of Corticosteroid-related Adverse Events Though Week 52
The rate of corticosteroid-related adverse events was calculated, and was adjusted by duration of study drug exposure.
Time frame: Baseline up to Week 52
This trial was conducted at 100 sites in 23 countries. Participants were randomized via in a 2:1:1 ratio to receive either upadacitinib 15 mg or 7.5 mg once daily in combination with a predefined 26-week CS taper regimen, or placebo with a predefined 52-week CS taper regimen
| Milestone | Placebo + 52-week CS Taper | 7.5 mg Upadacitinib + 26-week CS Taper | 15 mg Upadacitinib + 26-week CS Taper | Placebo + 52-week CS Taper -> Placebo | 7.5 mg Upadacitinib + 26-week CS Taper -> 7.5 mg Upadacitinib | 7.5 mg Upadacitinib + 26-week CS Taper -> Placebo | 15 mg Upadacitinib + 26-week CS Taper -> 15 mg Upadacitinib | 15 mg Upadacitinib + 26-week CS Taper -> Placebo |
|---|---|---|---|---|---|---|---|---|
| Started | 112 | 107 | 210 | 0 | 0 | 0 | 0 | 0 |
| Randomized | 112 | 107 | 210 | 0 | 0 | 0 | 0 | 0 |
| Received randomized study drug | 112 | 107 | 209 | 0 | 0 | 0 | 0 | 0 |
| Completed | 86 | 85 | 177 | 0 | 0 | 0 | 0 | 0 |
| Not completed | 26 | 22 | 33 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Adverse event | 13 | 11 | 17 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Withdrew consent | 5 | 6 | 10 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Covid-19 logistical restrictions | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Failure to meet continuation criteria | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Other, not specified | 5 | 5 | 5 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Did not receive randomized study drug | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 |
| Milestone | Placebo + 52-week CS Taper | 7.5 mg Upadacitinib + 26-week CS Taper | 15 mg Upadacitinib + 26-week CS Taper | Placebo + 52-week CS Taper -> Placebo | 7.5 mg Upadacitinib + 26-week CS Taper -> 7.5 mg Upadacitinib | 7.5 mg Upadacitinib + 26-week CS Taper -> Placebo | 15 mg Upadacitinib + 26-week CS Taper -> 15 mg Upadacitinib | 15 mg Upadacitinib + 26-week CS Taper -> Placebo |
|---|---|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 43 | 39 | 14 | 92 | 35 |
| Completed | 0 | 0 | 0 | 38 | 38 | 12 | 85 | 30 |
| Not completed | 0 | 0 | 0 | 5 | 1 | 2 | 7 | 5 |
| Withdrew: Adverse event | 0 | 0 | 0 | 1 | 1 | 2 | 4 | 2 |
| Withdrew: Withdrew consent | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 2 |
| Withdrew: Lost to follow-up | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 |
| Withdrew: Failure to meet continuation criteria | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 |
| Withdrew: Other, not specified | 0 | 0 | 0 | 2 | 0 | 0 | 1 | 1 |
Sustained remission is defined as having achieved absence of giant cell arteritis (GCA) signs and symptoms from Week 12 through Week 52, and adherence to the protocol-defined corticosteroid (CS) taper regimen.
| percentage of participants | Placebo + 52-week CS Taper | 7.5 mg Upadacitinib + 26-week CS Taper | 15 mg Upadacitinib + 26-week CS Taper |
|---|---|---|---|
| Percentage of Participants Achieving Sustained Remission at Week 52 | 29.0 (20.6 to 37.5) | 41.1 (31.8 to 50.4) | 46.4 (39.6 to 53.2) |
Sustained complete remission is defined as having absence of giant cell arteritis (GCA) signs and symptoms from Week 12 through Week 52; normalization of erythrocyte sedimentation rate (ESR); normalization of high sensitivity C-reactive protein (hs-CRP) and adherence to the protocol-defined CS taper regimen.
| percentage of participants | Placebo + 52-week CS Taper | 7.5 mg Upadacitinib + 26-week CS Taper | 15 mg Upadacitinib + 26-week CS Taper |
|---|---|---|---|
| Percentage of Participants Achieving Sustained Complete Remission From Week 12 Through Week 52 | 16.1 (9.3 to 22.9) | 26.2 (17.8 to 34.5) | 37.1 (30.5 to 43.7) |
The cumulative exposure to corticosteroid(s) through Week 52 of the study was documented.
| mg | Placebo + 52-week CS Taper | 7.5 mg Upadacitinib + 26-week CS Taper | 15 mg Upadacitinib + 26-week CS Taper |
|---|---|---|---|
| Cumulative Corticosteroid (CS) Exposure Through Week 52 | 2882.0 (2762.00 to 3253.00) | 1905.0 (1615.00 to 2265.00) | 1615.0 (1615.00 to 1635.00) |
Disease flare is defined as an event determined by the investigator to represent recurrence of Giant Cell Arteritis (GCA) signs or symptoms or an erythrocyte sedimentation rate (ESR) measurement \> 30 mm/hr (attributable to GCA) AND requiring an increase in corticosteroid (CS) dose.
| days | Placebo + 52-week CS Taper | 7.5 mg Upadacitinib + 26-week CS Taper | 15 mg Upadacitinib + 26-week CS Taper |
|---|---|---|---|
| Time to First Disease Flare Through Week 52 | 323.0 (249.00 to NA) | NA (316.00 to NA) | NA (NA to NA) |
The percentage of participants who experience at least 1 disease flare was calculated. Disease flare is defined as an event determined by the investigator to represent recurrence of Giant Cell Arteritis (GCA) signs or symptoms or an erythrocyte sedimentation rate (ESR) measurement \> 30 mm/hr (attributable to GCA) AND requiring an increase in corticosteroid (CS) dose.
| percentage of participants | Placebo + 52-week CS Taper | 7.5 mg Upadacitinib + 26-week CS Taper | 15 mg Upadacitinib + 26-week CS Taper |
|---|---|---|---|
| Percentage of Participants Who Experience at Least 1 Disease Flare Through Week 52 | 55.6 (42.9 to 69.2) | 41.3 (32.2 to 51.7) | 34.3 (27.4 to 42.4) |
Complete remission is defined as having achieved absence of Giant Cell Arteritis (GCA) signs and symptoms; normalization of erythrocyte sedimentation rate (ESR) to \< 30 mm/hr-- if ESR ≥30 mm/hr and elevation is not attributable to GCA, this criterion can still be met); normalization of high sensitivity C-reactive protein (hs-CRP) to \< 1 mg/dL; and adherence to the protocol-defined corticosteroid (CS) taper regimen.
| percentage of participants | Placebo + 52-week CS Taper | 7.5 mg Upadacitinib + 26-week CS Taper | 15 mg Upadacitinib + 26-week CS Taper |
|---|---|---|---|
| Percentage of Participants in Complete Remission at Week 52 | 19.6 (12.3 to 27.0) | 43.0 (33.6 to 52.4) | 50.2 (43.4 to 57.1) |
Complete remission is defined as having achieved absence of Giant Cell Arteritis (GCA) signs and symptoms; normalization of erythrocyte sedimentation rate (ESR) to \< 30 mm/hr-- if ESR ≥30 mm/hr and elevation is not attributable to GCA, this criterion can still be met); normalization of high sensitivity C-reactive protein (hs-CRP) to \< 1 mg/dL; and adherence to the protocol-defined corticosteroid (CS) taper regimen.
| percentage of participants | Placebo + 52-week CS Taper | 7.5 mg Upadacitinib + 26-week CS Taper | 15 mg Upadacitinib + 26-week CS Taper |
|---|---|---|---|
| Percentage of Participants in Complete Remission at Week 24 | 36.1 (27.2 to 45.1) | 39.3 (30.0 to 48.5) | 57.2 (50.5 to 64.0) |
The Short Form 36-Item Health Survey (SF-36) Version 2 is a self-administered questionnaire that measures the impact of disease on overall quality of life during the past 4 weeks. The SF-36 consists of 36 questions in eight domains (physical function, pain, general and mental health, vitality, social function, physical and emotional health). The physical component summary (PCS) is a weighted combination of the 8 subscales with positive weighting for physical functioning, role-physical, bodily pain, and general health. The SF-36 PCS ranges from 0 to 100. A linear algorithm was applied to the calculation of the PCS which has a normative mean value of 50. Higher scores are associated with less disability; a score of 100 is equivalent to no disability and a score of 0 is equivalent to maximum disability. A positive change from the Baseline score indicates improvement.
| units on a scale | Placebo + 52-week CS Taper | 7.5 mg Upadacitinib + 26-week CS Taper | 15 mg Upadacitinib + 26-week CS Taper |
|---|---|---|---|
| Change From Baseline in the 36-item Short Form Quality of Life Questionnaire (SF-36) Physical Component Summary (PCS) Score at Week 52 | -1.2892 (-3.3093 to 0.7309) | 1.3202 (-0.6553 to 3.2957) | 2.4634 (1.1707 to 3.7561) |
The number of disease flares per participant during Period 1 was documented, and was adjusted by the duration of study participation.
| Disease Flare per Participant per Year | Placebo + 52-week CS Taper | 7.5 mg Upadacitinib + 26-week CS Taper | 15 mg Upadacitinib + 26-week CS Taper |
|---|---|---|---|
| Number of Disease Flares Per Participant Through Week 52 | 0.7 (0.5 to 0.9) | 0.6 (0.4 to 0.7) | 0.4 (0.3 to 0.5) |
The FACIT-Fatigue questionnaire is a self-administered patient questionnaire that consists of 13 questions designed to measure the degree of fatigue experienced by participants in the previous 7 days, including physical fatigue, functional fatigue, emotional fatigue, and social consequences of fatigue. Participants respond to the questions on a scale from 0 (not at all) to 4 (very much). The FACIT-Fatigue score is computed by summing the item scores, after reversing items worded in the negative direction. The FACIT-Fatigue score ranges from 0 to 52, where higher scores represent less fatigue. A positive change from Baseline indicates improvement.
| units on a scale | Placebo + 52-week CS Taper | 7.5 mg Upadacitinib + 26-week CS Taper | 15 mg Upadacitinib + 26-week CS Taper |
|---|---|---|---|
| Change From Baseline in Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-Fatigue) at Week 52 | -2.4 (-4.71 to -0.07) | 1.1 (-1.17 to 3.37) | 1.7 (0.18 to 3.14) |
The Treatment Satisfaction Questionnaire for Medications (TSQM) is a generic ePRO measure of treatment satisfaction, developed to compare treatment satisfaction between medication types and conditions. TSQM comprises of 14 items to assess 4 domains (effectiveness, side effects, convenience, and global satisfaction). The TSQM items are rated on a Likert scale (1 = extremely dissatisfied to 7 = extremely satisfied). Scores for each of the 4 domains range from 0 to 100, with higher scores corresponding to higher satisfaction. A positive change from Baseline indicates improvement.
| units on a scale | Placebo + 52-week CS Taper | 7.5 mg Upadacitinib + 26-week CS Taper | 15 mg Upadacitinib + 26-week CS Taper |
|---|---|---|---|
| Assessment of Treatment Satisfaction Questionnaire for Medication (TSQM) Patient Global Satisfaction Subscale at Week 52 | 68.8428 (63.8310 to 73.8547) | 74.2644 (69.4483 to 79.0805) | 71.5753 (68.3375 to 74.8131) |
The rate of corticosteroid-related adverse events was calculated, and was adjusted by duration of study drug exposure.
| CS-related AE per participant per year | Placebo + 52-week CS Taper | 7.5 mg Upadacitinib + 26-week CS Taper | 15 mg Upadacitinib + 26-week CS Taper |
|---|---|---|---|
| Rate of Corticosteroid-related Adverse Events Though Week 52 | 1.7 (1.3 to 2.3) | 1.7 (1.2 to 2.2) | 2.0 (1.7 to 2.4) |
Collected over All-cause mortality and adverse events were collected from the time informed consent was signed through the end of the study. Median time on follow-up was 378 days for Pbo (Period 1); 377 days for Upa 7.5 mg (Period 1); 378 days for Upa 15 mg (Period 1); 364 days for Pbo -> Pbo (Period 2); 364 days for 7.5 mg Upa -> 7.5 mg Upa (Period 2); 363.5 days for 7.5 mg Upa -> Pbo (Period 2); 364 days for 15 mg Upa -> 15 mg Upa (Period 2); and 364 days for 15 mg Upa -> Pbo (Period 2).. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo + 52-week CS Taper | 2/112 (1.8%) | 24/112 (21.4%) | 90/112 (80.4%) |
| 7.5 mg Upadacitinib + 26-week CS Taper | 0/107 (0%) | 14/107 (13.1%) | 88/107 (82.2%) |
| 15 mg Upadacitinib + 26-week CS Taper | 3/210 (1.4%) | 50/210 (23.8%) | 174/210 (82.9%) |
| Placebo + 52-week CS Taper -> Placebo | 0/43 (0%) | 9/43 (20.9%) | 34/43 (79.1%) |
| 7.5 mg Upadacitinib + 26-week CS Taper -> 7.5 mg Upadacitinib | 0/39 (0%) | 6/39 (15.4%) | 27/39 (69.2%) |
| 7.5 mg Upadacitinib + 26-week CS Taper -> Placebo | 0/14 (0%) | 1/14 (7.1%) | 12/14 (85.7%) |
| 15 mg Upadacitinib + 26-week CS Taper -> 15 mg Upadacitinib | 0/92 (0%) | 14/92 (15.2%) | 67/92 (72.8%) |
| 15 mg Upadacitinib + 26-week CS Taper -> Placebo | 0/35 (0%) | 5/35 (14.3%) | 31/35 (88.6%) |
| Event | Placebo + 52-week CS Taper | 7.5 mg Upadacitinib + 26-week CS Taper | 15 mg Upadacitinib + 26-week CS Taper | Placebo + 52-week CS Taper -> Placebo | 7.5 mg Upadacitinib + 26-week CS Taper -> 7.5 mg Upadacitinib | 7.5 mg Upadacitinib + 26-week CS Taper -> Placebo | 15 mg Upadacitinib + 26-week CS Taper -> 15 mg Upadacitinib | 15 mg Upadacitinib + 26-week CS Taper -> Placebo |
|---|---|---|---|---|---|---|---|---|
| ASTHMARespiratory, thoracic and mediastinal disorders | 0/112 | 0/107 | 0/210 | 0/43 | 0/39 | 1/14 | 0/92 | 0/35 |
| ATRIAL FIBRILLATIONCardiac disorders | 0/112 | 0/107 | 1/210 | 0/43 | 0/39 | 0/14 | 2/92 | 2/35 |
| PNEUMONIAInfections and infestations | 5/112 | 3/107 | 0/210 | 1/43 | 0/39 | 0/14 | 2/92 | 0/35 |
| LARGE INTESTINE POLYPGastrointestinal disorders | 0/112 | 0/107 | 0/210 | 0/43 | 0/39 | 0/14 | 0/92 | 1/35 |
| INTERVERTEBRAL DISC PROTRUSIONMusculoskeletal and connective tissue disorders | 1/112 | 0/107 | 0/210 | 0/43 | 0/39 | 0/14 | 0/92 | 1/35 |
| OSTEOARTHRITISMusculoskeletal and connective tissue disorders | 1/112 | 0/107 | 2/210 | 1/43 | 0/39 | 0/14 | 2/92 | 1/35 |
| DIVERTICULITISInfections and infestations | 0/112 | 0/107 | 0/210 | 0/43 | 1/39 | 0/14 | 0/92 | 0/35 |
| LUMBAR SPINAL STENOSISMusculoskeletal and connective tissue disorders | 0/112 | 1/107 | 0/210 | 1/43 | 1/39 | 0/14 | 0/92 | 0/35 |
| LUNG ADENOCARCINOMANeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/112 | 0/107 | 0/210 | 0/43 | 1/39 | 0/14 | 0/92 | 0/35 |
| PAPILLARY THYROID CANCERNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/112 | 0/107 | 0/210 | 0/43 | 1/39 | 0/14 | 0/92 | 0/35 |
| Event | Placebo + 52-week CS Taper | 7.5 mg Upadacitinib + 26-week CS Taper | 15 mg Upadacitinib + 26-week CS Taper | Placebo + 52-week CS Taper -> Placebo | 7.5 mg Upadacitinib + 26-week CS Taper -> 7.5 mg Upadacitinib | 7.5 mg Upadacitinib + 26-week CS Taper -> Placebo | 15 mg Upadacitinib + 26-week CS Taper -> 15 mg Upadacitinib | 15 mg Upadacitinib + 26-week CS Taper -> Placebo |
|---|---|---|---|---|---|---|---|---|
| GIANT CELL ARTERITISVascular disorders | 34/112 | 27/107 | 45/210 | 9/43 | 2/39 | 5/14 | 9/92 | 14/35 |
| ARTHRALGIAMusculoskeletal and connective tissue disorders | 15/112 | 7/107 | 28/210 | 10/43 | 1/39 | 1/14 | 12/92 | 3/35 |
| COVID-19Infections and infestations | 12/112 | 12/107 | 27/210 | 7/43 | 7/39 | 3/14 | 17/92 | 6/35 |
| HEADACHENervous system disorders | 13/112 | 16/107 | 33/210 | 2/43 | 3/39 | 0/14 | 14/92 | 1/35 |
| URINARY TRACT INFECTIONInfections and infestations | 17/112 | 15/107 | 21/210 | 1/43 | 3/39 | 1/14 | 4/92 | 1/35 |
| HYPERTENSIONVascular disorders | 13/112 | 16/107 | 28/210 | 2/43 | 2/39 | 0/14 | 6/92 | 5/35 |
| RESPIRATORY TRACT INFECTIONInfections and infestations | 0/112 | 1/107 | 3/210 | 1/43 | 2/39 | 2/14 | 2/92 | 1/35 |
| UPPER RESPIRATORY TRACT INFECTIONInfections and infestations | 8/112 | 8/107 | 11/210 | 2/43 | 0/39 | 2/14 | 6/92 | 1/35 |
| BACK PAINMusculoskeletal and connective tissue disorders | 14/112 | 6/107 | 25/210 | 1/43 | 0/39 | 2/14 | 5/92 | 3/35 |
| NASOPHARYNGITISInfections and infestations | 14/112 | 6/107 | 18/210 | 4/43 | 4/39 | 0/14 | 8/92 | 3/35 |
Full analysis set in Period 1 (FAS1): all randomized participants who received at least 1 dose of study drug in Period 1
| Age, Continuous(years) | Placebo + 52-week CS Taper | 7.5 mg Upadacitinib + 26-week CS Taper | 15 mg Upadacitinib + 26-week CS Taper | Total |
|---|---|---|---|---|
| Mean | 71.6 ± 7.33 | 71.1 ± 7.55 | 70.8 ± 7.31 | 71.1 ± 7.37 |
| Sex: Female, Male(Participants) | Placebo + 52-week CS Taper | 7.5 mg Upadacitinib + 26-week CS Taper | 15 mg Upadacitinib + 26-week CS Taper | Total |
|---|---|---|---|---|
| Female | 77 | 80 | 156 | 313 |
| Male | 35 | 27 | 53 | 115 |
| Ethnicity (NIH/OMB)(Participants) | Placebo + 52-week CS Taper | 7.5 mg Upadacitinib + 26-week CS Taper | 15 mg Upadacitinib + 26-week CS Taper | Total |
|---|---|---|---|---|
| Hispanic or Latino | 5 | 2 | 6 | 13 |
| Not Hispanic or Latino | 107 | 105 | 203 | 415 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Placebo + 52-week CS Taper | 7.5 mg Upadacitinib + 26-week CS Taper | 15 mg Upadacitinib + 26-week CS Taper | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 |
| Asian | 6 | 6 | 10 | 22 |
| Native Hawaiian or Other Pacific Islander | 0 | 1 | 0 | 1 |
| Black or African American | 2 | 1 | 0 | 3 |
| White | 103 | 99 | 199 | 401 |
| More than one race | 1 | 0 | 0 | 1 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
Showing the first 100 of 172 sites across 24 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — AbbVie is committed to responsible data sharing regarding the clinical trials we sponsor. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information (e.g., protocols, analyses plans, clinical study reports), as long as the trials are not part of an ongoing or planned regulatory submission. This includes requests for clinical trial data for unlicensed products and indications.
Supporting information: Study protocol, Statistical analysis plan, Clinical study report
Time frame: For details on when studies are available for sharing visit https://vivli.org/ourmember/abbvie/
Access criteria: Access to this clinical trial data can be requested by any qualified researchers who engage in rigorous independent scientific research, and will be provided following review and approval of a research proposal and statistical analysis plan and execution of a data sharing statement. Data requests can be submitted at any time after approval in the US and/or EU and a primary manuscript is accepted for publication. For more information on the process, or to submit a request, visit the following link https://www.abbvieclinicaltrials.com/hcp/data-sharing/
Data sharing details ↗ · vivli.org
Ran from Jan 2019 to primary completion in Feb 2024, 60 months.
Results were first posted in Mar 2025, 1 year 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Upadacitinib